Insider Buying: Shield Therapeutics plc (LON:STX) Insider Acquires 575,000 Shares of Stock

Shield Therapeutics plc (LON:STX) insider Anders Lundstrom bought 575,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($28,949.02).

Shield Therapeutics Stock Up 8.9 %

Shares of LON STX opened at GBX 4.14 ($0.05) on Friday. The business has a 50-day moving average of GBX 2.78 and a two-hundred day moving average of GBX 3.37. The company has a market capitalization of £40.83 million, a price-to-earnings ratio of -1.07 and a beta of 1.42. Shield Therapeutics plc has a 1 year low of GBX 1.06 ($0.01) and a 1 year high of GBX 5.95 ($0.07). The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.